Status:
COMPLETED
Efficacy and Safety of Single Versus Double Ritonavir-boosted Protease Inhibitor (PI)-Based Antiretroviral Therapy (ART) Regimens
Lead Sponsor:
The HIV Netherlands Australia Thailand Research Collaboration
Collaborating Sponsors:
Ministry of Education, Thailand
Conditions:
HIV Infection
HIV Infections
Eligibility:
All Genders
1-18 years
Brief Summary
The virological efficacy will be no different in children treated with single versus double boosted PI second line ART regimens.
Detailed Description
A total of 50,620 Thai children have been diagnosed with HIV infection in Thailand between 1988 and 2005, of whom only 20,000 are still living.1 The production of generic ART by the Thai Government Ph...
Eligibility Criteria
Inclusion
- Children (\< 18 years old) with HIV infection
- Have failed NNRTI-based ART
- Received second-line regimen with either one or two boosted PIs (Note: low dose ritonavir to boost the other PI will not be count as additional PI)
- Began ritonavir-boosted PI prior to June 30, 2007
Exclusion
- Have previously received PI treatment for longer than 30 days prior to the current PI regimen.
- Has previously or currently been treated with abacavir or tenofovir
- Currently on ART other than NRTI, NNRTI and PI drug classes
Key Trial Info
Start Date :
October 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT00886990
Start Date
October 1 2007
End Date
April 1 2009
Last Update
July 17 2020
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Petchburi Hospital
Petchburi, Petchburi, Thailand
2
HIV-NAT
Bangkok, Thailand, 10330
3
Queen Sirikit National Institute of Child Health
Bangkok, Thailand
4
Siriraj Hospital, Mahidol University
Bangkok, Thailand